Analysts’ Viewpoint
Increase in prevalence of chronic diseases, advances in stem cell research, and growth in investment in regenerative medicine are prominent factors fueling allogeneic stem cell market growth. Rise in demand for personalized medicine is also one of the key growth frontiers of the allogeneic stem cell market. Furthermore, increase in investment in regenerative medicine is projected to boost market trajectory in the near future.
Companies in the global market are capitalizing on the synergistic potential between allogeneic stem cells and cutting-edge modalities such as gene editing and immunotherapy. Market players are primarily involved in strategic partnerships with other players to create value-grab allogeneic stem cell market opportunities.
Allogeneic stem cell transplantation, also known as allogeneic hematopoietic stem cell transplantation (HSCT), is a medical procedure in which stem cells are transferred from a healthy donor to a recipient to treat various diseases. The donor can be a family member (usually a sibling) or an unrelated individual whose tissue type matches with the recipient. Human leukocyte antigen (HLA) matching is essential to minimize the risk of graft rejection, graft-versus-host disease (GvHD), and other complications.
Stem cells used in allogeneic transplantation can be obtained from different sources, including bone marrow, peripheral blood, and umbilical cord blood. Bone marrow was traditionally the most common source, but peripheral blood stem cells (PBSCs) and umbilical cord blood are now regularly used due to easier collection and higher stem cell yield.
Integration of biomaterials and tissue engineering with allogeneic stem cell transplantation holds significant potential for regenerative medicine. Biomaterial scaffolds provide physical support and guidance for stem cell growth and differentiation, thus enhancing their therapeutic efficacy. Development of bioengineered tissues and organs through the combination of allogeneic stem cells and biomaterials opens up new avenues for the treatment of complex diseases and injuries. These are some of the recent developments in the allogeneic stem cell market that are contributing to industry growth.
Of late, there has been a substantial increase in understanding of stem cell biology, including identification and characterization of different stem cell types. Advances in stem cell research have led to the discovery of new sources of stem cells, such as mesenchymal stem cells (MSCs) derived from various tissues. This expansion in knowledge base enables researchers to explore and harness the potential of different stem cell populations for allogeneic transplantation.
Technological advancements play a crucial role in augmenting market progress. Improved methods for stem cell isolation, purification, and expansion have made it possible to obtain an adequate number of cells for transplantation.
Techniques such as ex vivo expansion, cell culture optimization, and cryopreservation have enhanced the availability and quality of allogeneic stem cells, thus facilitating their clinical application.
Allogeneic stem cell transplantation has been widely used in the treatment of hematological malignancies such as leukemia, lymphoma, and multiple myeloma. It offers the potential for complete remission and long-term disease control, particularly in cases where conventional treatments have failed. The ability of allogeneic stem cells to replace the diseased hematopoietic system and induce a graft-versus-leukemia effect contributes to its therapeutic success.
The therapeutic potential of allogeneic stem cell transplantation extends beyond hematological malignancies. It is increasingly being explored for non-hematological disorders, including genetic disorders, autoimmune diseases, and degenerative conditions.
Allogeneic stem cells have the capacity to differentiate into specialized cell types and secrete immunomodulatory factors, thus offering potential regenerative and immunoregulatory benefits.
The t-cell depleted transplant type segment is likely to dominate the global market in the near future. T-cell depletion is a technique used during allogeneic stem cell transplantation to reduce the risk of graft-versus-host disease (GvHD), a potentially serious complication.
T-cell depletion is an effective strategy for preventing GvHD, which occurs when the donor's immune cells recognize the recipient's tissues as foreign and attack them. The risk of GvHD can be significantly reduced by removing T-cells from the donor stem cell graft. This has led to the widespread adoption of T-cell depletion techniques in allogeneic stem cell transplantation.
Adipose tissue, commonly known as fat tissue, is a rich source of mesenchymal stem cells (MSCs), which have shown promising potential for various therapeutic applications due to their regenerative and immunomodulatory properties.
Adipose-derived stem cells have been gaining traction; however, other sources such as bone marrow-derived stem cells, umbilical cord blood-derived stem cells, and induced pluripotent stem cells (iPSCs) also contribute to market growth. These stem cells can differentiate into various cell types, including adipocytes, chondrocytes, and osteocytes. Thus, adipose-derived stem cells are valuable for tissue repair and regeneration.
Musculoskeletal diseases encompass a range of conditions that affect the bones, muscles, joints, ligaments, and tendons. These conditions can cause pain and limited mobility, thus adversely impacting the quality of life.
Allogeneic stem cell therapies have been explored as a potential treatment option for musculoskeletal disorders such as osteoarthritis, rheumatoid arthritis, tendinopathy, and even bone fractures.
Regenerative and anti-inflammatory properties of stem cells could help repair damaged tissues and promote healing. Thus, rise in incidence of musculoskeletal diseases is bolstering market dynamics.
Hospital is a key end-user segment for stem cell therapies due to the role it plays in providing medical care, specialized treatments, and a controlled environment for advanced procedures. Stem cell therapies, including allogeneic approaches, often require specialized facilities and medical expertise to ensure proper administration and patient monitoring.
Hospitals are equipped with the necessary infrastructure, medical professionals, and resources to carry out these therapies effectively and safely.
According to the latest allogeneic stem cell market research, North America is likely to dominate the global landscape in the near future. The presence of advanced healthcare infrastructure, research institutions, and regulatory frameworks that facilitate clinical trials in the U.S. and Canada has contributed to market expansion in the region.
The allogeneic stem cell market size in Europe is anticipated to increase at a steady pace during the forecast period, owing to the rise in stem cell research and clinical trials in the region. Germany, the U.K., and France have strong scientific communities and healthcare systems that support stem cell research and therapy development.
The allogeneic stem cell market in Asia Pacific has been gaining momentum since the last few years due to the improvement in healthcare infrastructure and rise in research activities in the region. China, Japan, and South Korea have made significant strides in stem cell research and clinical applications.
The global landscape is fragmented, with the presence of several leading players that control majority of the allogeneic stem cell market share. According to the allogeneic stem cell market forecast, companies are implementing innovative strategies, including partnerships, mergers, and acquisitions, to increase their industry share.
Mesoblast Limited, Gamida Cell Ltd., Novartis International AG, Cellectis SA, Magenta Therapeutics Inc., Fate Therapeutics Inc., Cynata Therapeutics Limited, Kiadis Pharma N.V., Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co., Ltd., Pluristem Therapeutics Inc., Celularity Inc., Lineage Cell Therapeutics Inc., Nohla Therapeutics Inc., and Orchard Therapeutics plc. are some of the leading players in the global market. These companies are following the allogeneic stem cell market trends to avail lucrative revenue opportunities.
The allogeneic stem cell market report profiles key players based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
|
Market Value in 2022 |
US$ 941.8 Mn |
|
Market Forecast Value in 2031 |
More than US$ 1.6 Bn |
|
Growth Rate (CAGR) |
6.3% |
|
Forecast Period |
2023-2031 |
|
Historical Data Available for |
2017-2021 |
|
Quantitative Units |
US$ Mn/Bn for Value |
|
Market Analysis |
It includes segment analysis and regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It was valued at US$ 941.8 Mn in 2022
It is projected to reach more than US$ 1.6 Bn by 2031
The CAGR is anticipated to be 6.3% from 2023 to 2031
Increase in prevalence of chronic diseases and growth in investment in regenerative medicine
North America is projected to be a highly lucrative region during the forecast period
Mesoblast Limited, Gamida Cell Ltd., Novartis International AG, Cellectis SA, Magenta Therapeutics Inc., Fate Therapeutics Inc., Cynata Therapeutics Limited, Kiadis Pharma N.V., Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co., Ltd., Pluristem Therapeutics Inc., Celularity Inc., Lineage Cell Therapeutics Inc., Nohla Therapeutics Inc., and Orchard Therapeutics plc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Allogeneic Stem Cell Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Allogeneic Stem Cell Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Insights on Trends in Allogeneic Stem Cell Transplantation
5.2. Technological Advancements
5.3. Regulatory Scenario by Region/Globally
5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Allogeneic Stem Cell Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017-2031
6.3.1. Unmodified Stem Cell Transplant
6.3.2. T-cell Depleted Transplant
6.3.3. Cord Blood Transplant
6.3.4. Donor Lymphocyte Infusion (DLI)
6.4. Market Attractiveness Analysis, by Type
7. Global Allogeneic Stem Cell Market Analysis and Forecast, by Cell Source
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Cell Source, 2017-2031
7.3.1. Bone Marrow
7.3.2. Peripheral Blood Stem Cell (PBSC)
7.3.3. Umbilical Cord Blood
7.3.4. Adipose Tissue
7.3.5. Others
7.4. Market Attractiveness Analysis, by Cell Source
8. Global Allogeneic Stem Cell Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Musculoskeletal Disease
8.3.2. Cardiovascular Disease
8.3.3. Autoimmune Disease
8.3.4. Cancer
8.3.5. GvHD
8.3.6. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Allogeneic Stem Cell Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. Hospital
9.3.2. Ambulatory Surgical Center
9.3.3. Others
9.4. Market Attractiveness Analysis, by End-user
10. Global Allogeneic Stem Cell Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Country/Region
11. North America Allogeneic Stem Cell Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017-2031
11.2.1. Unmodified Stem Cell Transplant
11.2.2. T-cell Depleted Transplant
11.2.3. Cord Blood Transplant
11.2.4. Donor Lymphocyte Infusion (DLI)
11.3. Market Value Forecast, by Cell Source, 2017-2031
11.3.1. Bone Marrow
11.3.2. Peripheral Blood Stem Cell (PBSC)
11.3.3. Umbilical Cord Blood
11.3.4. Adipose Tissue
11.3.5. Others
11.4. Market Value Forecast, by Application, 2017-2031
11.4.1. Musculoskeletal Disease
11.4.2. Cardiovascular Disease
11.4.3. Autoimmune Disease
11.4.4. Cancer
11.4.5. GvHD
11.4.6. Others
11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. Hospital
11.5.2. Ambulatory Surgical Center
11.5.3. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Cell Source
11.7.3. By Application
11.7.4. By End-user
11.7.5. By Country/Sub-region
12. Europe Allogeneic Stem Cell Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017-2031
12.2.1. Unmodified Stem Cell Transplant
12.2.2. T-cell Depleted Transplant
12.2.3. Cord Blood Transplant
12.2.4. Donor Lymphocyte Infusion (DLI)
12.3. Market Value Forecast, by Cell Source, 2017-2031
12.3.1. Bone Marrow
12.3.2. Peripheral Blood Stem Cell (PBSC)
12.3.3. Umbilical Cord Blood
12.3.4. Adipose Tissue
12.3.5. Others
12.4. Market Value Forecast, by Application, 2017-2031
12.4.1. Musculoskeletal Disease
12.4.2. Cardiovascular Disease
12.4.3. Autoimmune Disease
12.4.4. Cancer
12.4.5. GvHD
12.4.6. Others
12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. Hospital
12.5.2. Ambulatory Surgical Center
12.5.3. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Cell Source
12.7.3. By Application
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Allogeneic Stem Cell Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017-2031
13.2.1. Unmodified Stem Cell Transplant
13.2.2. T-cell Depleted Transplant
13.2.3. Cord Blood Transplant
13.2.4. Donor Lymphocyte Infusion (DLI)
13.3. Market Value Forecast, by Cell Source, 2017-2031
13.3.1. Bone Marrow
13.3.2. Peripheral Blood Stem Cell (PBSC)
13.3.3. Umbilical Cord Blood
13.3.4. Adipose Tissue
13.3.5. Others
13.4. Market Value Forecast, by Application, 2017-2031
13.4.1. Musculoskeletal Disease
13.4.2. Cardiovascular Disease
13.4.3. Autoimmune Disease
13.4.4. Cancer
13.4.5. GvHD
13.4.6. Others
13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. Hospital
13.5.2. Ambulatory Surgical Center
13.5.3. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Cell Source
13.7.3. By Application
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Allogeneic Stem Cell Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017-2031
14.2.1. Unmodified Stem Cell Transplant
14.2.2. T-cell Depleted Transplant
14.2.3. Cord Blood Transplant
14.2.4. Donor Lymphocyte Infusion (DLI)
14.3. Market Value Forecast, by Cell Source, 2017-2031
14.3.1. Bone Marrow
14.3.2. Peripheral Blood Stem Cell (PBSC)
14.3.3. Umbilical Cord Blood
14.3.4. Adipose Tissue
14.3.5. Others
14.4. Market Value Forecast, by Application, 2017-2031
14.4.1. Musculoskeletal Disease
14.4.2. Cardiovascular Disease
14.4.3. Autoimmune Disease
14.4.4. Cancer
14.4.5. GvHD
14.4.6. Others
14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. Hospital
14.5.2. Ambulatory Surgical Center
14.5.3. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Cell Source
14.7.3. By Application
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Allogeneic Stem Cell Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017-2031
15.2.1. Unmodified Stem Cell Transplant
15.2.2. T-cell Depleted Transplant
15.2.3. Cord Blood Transplant
15.2.4. Donor Lymphocyte Infusion (DLI)
15.3. Market Value Forecast, by Cell Source, 2017-2031
15.3.1. Bone Marrow
15.3.2. Peripheral Blood Stem Cell (PBSC)
15.3.3. Umbilical Cord Blood
15.3.4. Adipose Tissue
15.3.5. Others
15.4. Market Value Forecast, by Application, 2017-2031
15.4.1. Musculoskeletal Disease
15.4.2. Cardiovascular Disease
15.4.3. Autoimmune Disease
15.4.4. Cancer
15.4.5. GvHD
15.4.6. Others
15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. Hospital
15.5.2. Ambulatory Surgical Center
15.5.3. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Type
15.7.2. By Cell Source
15.7.3. By Application
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Mesoblast Limited
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Gamida Cell Ltd.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Novartis International AG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Cellectis SA
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Magenta Therapeutics Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Fate Therapeutics Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Cynata Therapeutics Limited
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Kiadis Pharma N.V.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Takeda Pharmaceutical Company Limited
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. JCR Pharmaceuticals Co., Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
16.3.11. Pluristem Therapeutics Inc.
16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.11.2. Product Portfolio
16.3.11.3. Financial Overview
16.3.11.4. SWOT Analysis
16.3.11.5. Strategic Overview
16.3.12. Celularity Inc.
16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.12.2. Product Portfolio
16.3.12.3. Financial Overview
16.3.12.4. SWOT Analysis
16.3.12.5. Strategic Overview
16.3.13. Lineage Cell Therapeutics Inc.
16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.13.2. Product Portfolio
16.3.13.3. Financial Overview
16.3.13.4. SWOT Analysis
16.3.13.5. Strategic Overview
16.3.14. Nohla Therapeutics Inc.
16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.14.2. Product Portfolio
16.3.14.3. Financial Overview
16.3.14.4. SWOT Analysis
16.3.14.5. Strategic Overview
16.3.15. Orchard Therapeutics plc
16.3.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.15.2. Product Portfolio
16.3.15.3. Financial Overview
16.3.15.4. SWOT Analysis
16.3.15.5. Strategic Overview
16.3.16. Other Prominent Players
16.3.16.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.16.2. Product Portfolio
16.3.16.3. Financial Overview
16.3.16.4. SWOT Analysis
16.3.16.5. Strategic Overview
List of Tables
Table 01: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 02: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
Table 03: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 04: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 05: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 08: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
Table 09: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 10: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 11: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 13: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
Table 14: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 15: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 16: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 18: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
Table 19: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 20: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 23: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
Table 24: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 25: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 26: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 28: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Cell Source, 2017-2031
Table 29: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 30: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, by End-user, 2017-2031
List of Figures
Figure 01: Global Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
Figure 02: Allogeneic Stem Cell Market Value Share, by Type, 2022
Figure 03: Allogeneic Stem Cell Market Value Share, by Cell Source, 2022
Figure 04: Allogeneic Stem Cell Market Value Share, by Application, 2022
Figure 05: Allogeneic Stem Cell Market Value Share, by End-user, 2022
Figure 06: Global Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
Figure 07: Global Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
Figure 08: Global Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
Figure 09: Global Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
Figure 10: Global Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
Figure 11: Global Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
Figure 12: Global Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
Figure 13: Global Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
Figure 14: Global Allogeneic Stem Cell Market Value Share Analysis, by Region, 2022 and 2031
Figure 15: Global Allogeneic Stem Cell Market Attractiveness Analysis, by Region, 2023-2031
Figure 16: North America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
Figure 17: North America Allogeneic Stem Cell Market Value Share Analysis, by Country, 2022 and 2031
Figure 18: North America Allogeneic Stem Cell Market Attractiveness Analysis, by Country, 2023-2031
Figure 19: North America Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
Figure 20: North America Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
Figure 21: North America Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
Figure 22: North America Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
Figure 23: North America Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
Figure 24: North America Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
Figure 25: North America Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
Figure 26: North America Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
Figure 27: Europe Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
Figure 28: Europe Allogeneic Stem Cell Market Value Share Analysis, by Country, 2022 and 2031
Figure 29: Europe Allogeneic Stem Cell Market Attractiveness Analysis, by Country, 2023-2031
Figure 30: Europe Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
Figure 31: Europe Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
Figure 32: Europe Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
Figure 33: Europe Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
Figure 34: Europe Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
Figure 35: Europe Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
Figure 36: Europe Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
Figure 37: Europe Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
Figure 38: Asia Pacific Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
Figure 39: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 40: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 41: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
Figure 42: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
Figure 43: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
Figure 44: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
Figure 45: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
Figure 46: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
Figure 47: Asia Pacific Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
Figure 48: Asia Pacific Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
Figure 49: Latin America Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
Figure 50: Latin America Allogeneic Stem Cell Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 51: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 52: Latin America Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
Figure 53: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
Figure 54: Latin America Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
Figure 55: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source, 2023-2031
Figure 56: Latin America Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
Figure 57: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, Application, 2023-2031
Figure 58: Latin America Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
Figure 59: Latin America Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
Figure 60: Middle East & Africa Allogeneic Stem Cell Market Value (US$ Mn) Forecast, 2017-2031
Figure 61: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 62: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 63: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by Type, 2022 and 2031
Figure 64: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by Type, 2023-2031
Figure 65: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by Cell Source, 2022 and 2031
Figure 66: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by Cell Source 2023-2031
Figure 67: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by Application, 2022 and 2031
Figure 68: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by Application, 2023-2031
Figure 69: Middle East & Africa Allogeneic Stem Cell Market Value Share Analysis, by End-user, 2022 and 2031
Figure 70: Middle East & Africa Allogeneic Stem Cell Market Attractiveness Analysis, by End-user, 2023-2031
Figure 71: Global Allogeneic Stem Cell Market Share Analysis By Company (2022)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Allogeneic Stem Cell Market
